RxDoctor Payments Data

Deanne Babio

Nurse Practitioner · Easton, PANPI 1124681697

Payments from drug & device makers

$2,815in general payments, 2019–2025

Across 42 payments — averaging $67.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$547
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$406
  • Evoke Pharma, Inc.$351
  • AbbVie$330
  • Takeda Pharmaceuticals U.S.A., Inc.$306
  • Gilead$125
  • plus $749 from 8 others

What the payments were for

  • Food & beverage$2,815100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,815 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$38,235
Medicare patients
283
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase39$65,646
LinzessLinaclotide31$32,146
Mesalamine25$14,228
PentasaMesalamine11$11,807
Pantoprazole Sodium337$4,308
Famotidine302$4,190
Esomeprazole Magnesium93$3,519
Lubiprostone16$2,462
Mesalamine ErMesalamine18$2,048
Omeprazole200$2,005
CholestyramineCholestyramine (With Sugar)20$1,972
Colestipol Hcl28$1,768
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl85$1,275
Dicyclomine Hcl51$1,169
Lactulose51$817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$330$97,79370 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Easton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →